Sun, H et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 71(3), 209-249 (2021).
Qiu, H., Cao, S. & Xu, R. Cancer incidence, mortality, and burden in China: a time-trend analysis and comparison with the United States and United Kingdom based on the global epidemiological data released in 2020. Cancer Commun. (London.) 41(10), 1037-1048 (2021).
Cao M, Li H, Sun D & Chen W Cancer burden of major cancers in China: A need for sustainable actions. Cancer Commun. (London.) 40(5), 205-210 (2020).
Zeng, H. et al. Changing cancer survival in China during 2003–15: A pooled analysis of 17 population-based cancer registries. Lancet Glob. Health 6(5), e555-e567 (2018).
Practice Bulletin Number 179. Breast cancer risk assessment and screening in average-risk women. fruit gynecol. 130(1), e1–e16 (2017).
Lilyquist J, Ruddy KJ, Vachon CM & Couch FJ Common genetic variation and breast cancer risk-past, present, and future. Cancer epidemic. biomark. prev 27(4), 380-394 (2018).
fanal, d et al. Breast cancer genome-wide association studies: There is strength in numbers. oncogenes 31(17), 2121-2128 (2012).
Carmeliet, P. & Jain, RK Molecular mechanisms and clinical applications of angiogenesis. Nature 473(7347), 298-307 (2011).
Saharinen P, Eklund L & Alitalo K. Therapeutic targeting of the angiopoietin-TIE pathway. nat. Rev. Drug Discov. 16(9), 635-661 (2017).
Konac, E. et al. Lack of association between − 460 C/T and 936 C/T of the vascular endothelial growth factor and angiopoietin-2 exon 4 G/A polymorphisms and ovarian, cervical, and endometrial cancers. DNA Cell Biol. 26(7), 453-463 (2007).
Bhatraju, PK et al. Genetic variation implicates plasma angiopoietin-2 in the development of acute kidney injury sub-phenotypes. BMC Nephrol. 21(1), 284 (2020).
Dai, C et al. Correlation between genetic polymorphism of angiopoietin-2 gene and clinical aspects of rheumatoid arthritis. international J.Med.Sci. 16(2), 331-336 (2019).
Hu, W et al. Correlations between angiopoietin-2 gene polymorphisms and lung cancer progression in a Chinese Han population. J.Cancer 10(13), 2935-2941 (2019).
World Medical, A. World Medical Association declaration of Helsinki: Ethical principles for medical research involving human subjects. JAMA 310(20), 2191-2194 (2013).
Elston, CW & Ellis, IO Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: Experience from a large study with long-term follow-up. Histopathology 19(5), 403-10 (1991).
Elston, CW & Ellis, IO Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: Experience from a large study with long-term follow-up. Histopathology 41(3A), 154-61 (2002).
Wang, CQ et al. Impacts of RETN genetic polymorphism on breast cancer development. J.Cancer 11(10), 2769-2777 (2020).
Wang, CQ et al. Fascin-1 as a novel diagnostic marker of triple-negative breast cancer. Cancer Med. 5(8), 1983-1988 (2016).
Wang, CQ et al. FSCN1 gene polymorphisms: Biomarkers for the development and progression of breast cancer. science representative 7(1), 15887 (2017).
you Z et al. Angiopoietin-2 gene polymorphisms are biomarkers for the development and progression of colorectal cancer in Han Chinese. international J.Med.Sci. 17(1), 97-102 (2020).
Zhang L, Zhang Y, Tang CH & Su CM RAD52 gene polymorphisms are associated with risk of colorectal cancer in a Chinese Han population. Medicine (Baltimore) 96(49), e8994 (2017).
Yang, YC et al. Melatonin reduces lung cancer stemness through inhibiting PLC, ERK, p38, beta-catenin, and twist pathways. environment Toxicol. 34(2), 203-209 (2019).
Chen, YA et al. Simvastatin sensitizes radioresistant prostate cancer cells by compromising DNA double-strand break repair. Front. Pharmacol. 9600 (2018).
King MC, Marks JH, Mandell JB New York Breast Cancer Study G. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science 302(5645), 643-6 (2003).
Stratton, MR & Rahman, N. The emerging landscape of breast cancer susceptibility. nat. genetics 40(1), 17-22 (2008).
Fanfani V, Zatopkova M, Harris AL, Pezzella F & Stracquadanio G. Dissecting the heritable risk of breast cancer: From statistical methods to susceptibility genes. Semin. Cancer Biol. 72175–184 (2021).
Yu K, Lee CH, Tan PH & Tan P. Conservation of breast cancer molecular subtypes and transcriptional patterns of tumor progression across distinct ethnic populations. clinical Cancer Res. 10(16), 5508-5517 (2004).
Fan, L et al. Breast cancer in China. Lancet Oncol. 15(7), e279-e289 (2014).
Makhoul, I. et al. Germline genetic variants in TEK, ANGPT1, ANGPT2, MMP9, FGF2 and VEGFA are associated with complete pathologic response to bevacizumab in breast cancer patients. PLoS One 12(1), e0168550 (2017).
Robson, M. et al. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N. Engl. J. Med. 377(6), 523-533 (2017).
Chai, Y et al. Homologous recombination deficiency (HRD) and BRCA 1/2 gene mutation for predicting the effect of platinum-based neoadjuvant chemotherapy of early-stage triple-negative breast cancer (TNBC): A systematic review and meta-analysis. J.Pers. medication 12(2), 323 (2022).
Blanco-Gomez, A. et al. Stromal SNAI2 Is required for ERBB2 breast cancer progression. Cancer Res. 80(23), 5216-5230 (2020).
Devlin, B. & Risch, N. A comparison of linkage disequilibrium measures for fine-scale mapping. genomics 29(2), 311-322 (1995).
Shifman, S. et al. A highly significant association between a COMT haplotype and schizophrenia. At the. J.Hum. genetics 71(6), 1296-1302 (2002).